A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)

NCT04457869 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Central Nervous System Lymphoma
Secondary Central Nervous System Lymphoma

Interventions

DRUG: F520

Sponsor

Shandong New Time Pharmaceutical Co., LTD